Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim highlights positive findings from AF drug trial

Boehringer Ingelheim highlights positive findings from AF drug trial

10th November 2010

Boehringer Ingelheim has highlighted newly-published clinical trial findings which illustrate the advantages of its atrial fibrillation (AF) drug Pradaxa (dabigatran etexilate).

A report in the Lancet Neurology journal has provided a sub-group analysis from the recent dabigatran etexilate study RE-LY, the largest AF outcomes trial ever completed.

It focused on 3,623 trial participants who had suffered a stroke or a transient ischemic attack, finding that Boehringer Ingelheim's treatment delivered significant benefits in terms of stroke and systemic embolism reduction compared to the control therapy.

This was consistent with the overall safety and efficacy results delivered by the RE-LY trial, which involved a total of 18,113 patients from 44 countries worldwide.

The strong clinical results supporting dabigatran etexilate have led to the treatment receiving approval in 75 countries worldwide.

Last month, Boehringer Ingelheim announced a new collaboration with MacroGenics, which will see the firms jointly create new drug compounds based on the Dual-Affinity Re-Targeting platform.ADNFCR-8000103-ID-800227197-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.